Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer

被引：0
|
作者：
Manegold, C [1 ]
机构：
[1] Thoraxklin, Dept Internal Med & Oncol, D-69126 Heidelberg, Germany
来源：
SEMINARS IN ONCOLOGY | 1998年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 22
页数：5
相关论文
共 50 条
  • [41] Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer
    CopleyMerriman, C
    Corral, J
    King, K
    Whiteside, R
    Voi, M
    Dorr, FA
    McDonald, RC
    LUNG CANCER, 1996, 14 (01) : 45 - 61
  • [42] Final results of randomized study of gemcitabine (G) plus cisplatin (P) versus etoposide (E) plus cisplatin in locally advanced or metastatic non small cell lung cancer (NSCLC)
    Bousahba, A., Sr.
    Bereksi-Reguig, F.
    Seghier, F.
    Boukerche, A.
    Dali-Youcef, A.
    Djellali, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Concurrent biweekly gemcitabine plus cisplatin chemotherapy and radiotherapy in patients with locally advanced non-small cell lung cancer
    Jung, M
    Kim, H
    Oak, C
    Jang, T
    Jeon, Y
    Jung, T
    LUNG CANCER, 2005, 49 : S170 - S170
  • [44] Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer
    J. R. Kroep
    E. F. Smit
    G. Giaccone
    K. Van der Born
    J. H. Beijnen
    C. J. Van Groeningen
    W. J. F. Van der Vijgh
    P. E. Postmus
    H. M. Pinedo
    G. J. Peters
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 509 - 516
  • [45] Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer
    Boyer, MJ
    Mitchell, P
    Goldstein, D
    Millward, MJ
    Olver, IN
    Clarke, SJ
    Richardson, G
    Davis, I
    LUNG CANCER, 2001, 32 (01) : 89 - 94
  • [46] Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
    A F Scinto
    V Ferraresi
    M Milella
    E Tucci
    C Santomaggio
    R Pasquali-Lasagni
    M R Del Vecchio
    N Campioni
    M Nardi
    F Cognetti
    British Journal of Cancer, 1999, 81 : 1031 - 1036
  • [47] A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer
    Cho, KH
    Song, YB
    Choi, IS
    Cho, EH
    Choi, JW
    Ahn, YM
    Roh, YH
    Nam, SH
    Kim, BS
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (01) : 50 - 54
  • [48] Concurrent versus sequential chemotherapy with hypofractionated radiotherapy in patients with inoperable locally advanced non-small cell lung cancer
    Guo, Wei
    Gu, Xiaobin
    Gao, Xianshu
    Ma, Mingwei
    Cui, Ming
    Xie, Mu
    Bai, Yun
    Peng, Chuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (07): : 10443 - 10452
  • [49] Single-agent gemcitabine in patients with resistant small-cell lung cancer
    van der Lee, I
    Smit, EF
    van Putten, JWG
    Groen, HJM
    Schlösser, NJJ
    Postmus, PE
    Schramel, FMNH
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 557 - 561
  • [50] Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC).
    Scagliotti, G
    Rossi, A
    Novello, S
    De Marinis, F
    Dogliotti, L
    Crinò, L
    Lorusso, V
    Martoni, A
    Paccagnella, A
    Gridelli, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 636S - 636S
12345